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The rational behind the use of allogeneic tumor cell lines
as therapeutical vaccines is that multiple antigens com-
mon to both, the immunizing cell line and the patient's
tumor are presented by shared human leukocyte antigen
(HLA) molecules. The cell line "KS" was established from
a malignant effusion of a breast cancer patient and found
to express an array of ubiquitous tumor associated anti-
gens (TAA) such as MUC-1, CEA, SSX-2, and members of
the MAGE-family. As a result of interferon(IFN)-γ stimula-
tion KS cells express high levels of HLA molecules, which
probably present multiple peptide ligands for polyclonal
T cell activation. This KS cell line was genetically modified
to express CD80 providing costimulatory signals to T lym-
phocytes, and further transfected to overexpress Her-2/
neu in order to avail a well characterized TAA as a marker
for immunodiagnostic. In vitro studies demonstrated: a)
KS24.22 transfectants can induce allospecific responses
through direct priming; b) activate cytotoxic T cells (CTL)
and TH cells; c) stimulate antigen-specific HLA-A*02-
restricted CTL after transfection with viral antigens; and d)
present TAA epitopes restricted by HLA-A*02. These
results supported the realisation of a phase-I/II clinical
trial, where KS24.22 cells are used to vaccinate patients
with breast cancer. KS24.22 were expanded under GMP
conditions and safety testing was done following FDA cri-
teria. The primary objectives of the study are toxicity and
feasibility. To correlate vaccine-induced immune
responses with clinical responses we evaluated KS24.22-
associated and TAA-specific T cells with a combination of
molecular and cellular immunodiagnostic tests (qRT-
PCR, ELISpot). Eligibility criteria included the following:
(1) measurable metastatic breast cancer; (2) patient
already received either anthracyclin- or taxan-based chem-
otherapy; (3) HLA-A*0201-positivity; (4) in vitro activa-
tion of patient's T cells by mitogen antibodies and
KS24.22 vaccine cells; (5) written informed consent.
Patients were excluded for following reasons: (1) immu-
nosuppressive or autoimmune diseases; (2) acute or sys-
temic infections; (3) chemotherapy or radiotherapy
within 4 weeks; (4) antibodies, cytokines, or other
immune therapies within 6 weeks. After irradiation, 107
cells were injected i.d. four times at 2-week intervals and
four times monthly. The protocol was approved by the the
local ethic-committees, the Paul-Ehrlich-Institut and the
Committee for Somatic Genetherapy of the Deutsche Ärz-
tekammer.
So far, 10 patients were included in this study receiving
together more then 70 vaccinations. Vaccinations showed
only minor side effects like flulike symptoms and injec-
tion site reactions. Here, the immunohistochemical anal-
ysis of biopsies showed infammatory cell infiltration
consisting of macrophages, dendritic cells and predomi-
nantly CD4+ T cells. Three patients had to discontinue
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therapy because of progression. Disease stabilisation was
observed in seven patients. Of these, postvaccination
PBMCs showed increasing KS24.22-reactive T cell
responses detected by quantifying antigen-induced IFN-γ-
mRNA. Two patients clearly developed HLA-A*02-
restricted, Her-2/neu-specific CD8+ T cells alongside with
KS24.22-related alloresponses. CEA- and MAGE-1-spe-
cific CD8+ T cells could be detected as well.
In summary, this immunization strategy proved to be safe
and feasible, and induced TAA-specific immune
responses. However, no objective tumor regressions were
observed so far. The qRT-PCR method proved to be highly
sensitive and can be used to perform an "immunologic
staging" under vaccination.Page 2 of 2
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